L-carnitine vs Metformin

L-carnitine (A-tier) vs Metformin (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

L-carnitine · tier A

Levocarnitine is an endogenous fatty-acid carrier with approved deficiency indications and modest, inconsistent weight-loss evidence. The approved injection is intravenous and indication-specific.

Across 37 randomized trials, supplementation produced a modest average weight change, while one direct oral trial in overweight women was negative. This evidence does not validate gray-market IM or SC injections.

-1.21 kg pooled mean body-weight difference · half-life 17.4 h apparent terminal value after the specified IV injection; not transferable to oral, IM, or SC products · weight loss

Metformin · tier D

Metformin is an established type 2 diabetes drug. Its diabetes outcomes do not establish healthy-human lifespan, healthspan, cognition, or muscle benefit, and randomized geroscience trials have been null or unfavorable on their primary claims.

UKPDS supports selected long-term outcomes in overweight people with newly diagnosed type 2 diabetes. MASTERS, MET-PREVENT, and METFORAGING do not establish a general healthy-aging benefit.

0.001 m/s MET-PREVENT walking-speed difference · half-life about 6.2 h in plasma and 17.6 h in blood in the immediate-release label record · focus

at a glance

• L-carnitine: tier A · -1.21 kg pooled mean body-weight difference
• Metformin: tier D · 0.001 m/s MET-PREVENT walking-speed difference

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.